VIDEO: Recent trials create excitement for EGFR-mutated lung cancer

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Last couple of years, we have seen a lot of new excitement in treating EGFR mutation lung cancer. I will have to comment on the frontline setting. We had two international global randomized phase three trial. Both of them showed a significant frontline benefit if you add intensification to current targeted therapy. So the first one is reported out as FLAURA2 that's the trial name, meaning that compare OC plus chemo versus osimertinib by itself showed significant progression-free survival benefit, and then the benefit seems to be lasting over time. The second international trial is called the MARIPOSA, where they add amivantamab, which is a EGFR med, by specific antibody to lazertinib, which is a similar third-generation EGFR TKI, compared to OC or compared to lazertinib by itself. In the MARIPOSA trial, the progression-free survival was also significantly improved.

Even more exciting, lately we've learned from press release that MARIPOSA regimen, meaning that amivantamab with lazertinib, render overall survival benefit to EGFR classical mutation patients in the metastatic setting. This is very exciting. The press release commented on potentially prolong over survival for over a year. So if you add the numbers up, osimertinib monotherapy give about a 36 to 38 months of overall survival, add another year, pushing to be on four years for our patients. So those data are so exciting that we're changing our frontline practice. Both of the regimens are approved in the United States and will be approved globally, so I think over the next couple of years, we'll see a major shift in the frontline practice.